Study on inpatient expenses and cost control strategies for breast cancer patients based on Diagnosis-Intervention Packet

基于诊断-干预包的乳腺癌患者住院费用及成本控制策略研究

阅读:1

Abstract

AIM: To provide reference information for reducing disease burden and promoting medical service. The inpatient expenses of breast cancer patients in a top-three public hospital in Zhengzhou under the background of Diagnosis-Intervention Packet (DIP) payment reform were analyzed, and corresponding cost control strategies were proposed. METHODS: In this study, 4,590 patients (3,311 before reform and 1,279 after reform) were finally included in this study. Student's t-test was used to compare the means of two samples. Chi-square test was used for the comparison of rates. The influencing factors of profit of the patients after reform were analyzed by binary logistic regression. RESULTS: Post-reform data revealed a significant reduction in medication costs and examination fees (P < 0.05), contributing to lower overall hospitalization expenses. The profit ratio of c50.9_86 (c50.9_86.0603: chemotherapy pump implantation surgery for unspecified breast malignant tumors) group was the highest, about 63.2%, and the loss ratio of c50.9_99 (c50.9_99.2503: intravenous injection of chemotherapy drugs for unspecified breast malignant tumors) group was the highest, about 66.7%. The length of hospital stay was the protective factor of profit, whereas the score of disease and employee insurance were the risk factors of profit. CONCLUSION: The DIP reform significantly reduced medication costs outside of surgery. Under the DIP payment mode reform policy, hospitals should strengthen the awareness of cost control and reduce medical costs, optimize the score of disease and group setting, pay attention to optimize disease structure and ensure fair access to treatment for patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。